Navigation Links
BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
Date:1/14/2009

ch statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking information. These risks include, but are not limited to, those associated with our capacity to finance our activities, the adequacy, timing, and results of our clinical trials, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, the success of research and development programs, reliance on subcontractors and key personnel, and other risks and uncertainties detailed from time-to-time in our filings with the Canadian securities commissions.

Readers should not place undue reliance on the forward-looking information, given that (i) our actual results could differ materially from a conclusion, forecast or projection in the forward-looking information, and (ii) certain material factors or assumptions which were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, could prove to be inaccurate. Additional information about (i) the material factors that could cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information, and (ii) the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, is contained in the Company's annual report and other documents filed from time to time with the Canadian securities commissions which are available at www.sedar.com. These statements speak only as of the date they are made, and we assume no obligation to revise such statements as a result of any event, circumst
'/>"/>

SOURCE BioSyntech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. West Concludes Agreement with Nektar
4. Workforce Alliance Concludes Three-Year Biotech Training Program
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Huge event with ... future pharma industry health, analysis and forecasting   ... the closing of its most successful show to date ... 2,500 exhibitors. Held this year in Paris ... key players from 140+ countries representing every step of ...
(Date:10/31/2014)... 30, 2014 Caustic soda is utilized in ... polycarbonates. At present, China takes lead in the global caustic ... possesses a number of facilities in the USA, Germany, Brazil ... caustic soda market in terms of output and production capacities. ... on average by 3% per year in the years ahead. ...
(Date:10/31/2014)... October 30, 2014 Two separate ... were hosted by Charm Sciences at its Andover, ... week in the US, the participants discussed international ... hygiene management, and process verification, and received hands-on ... This was the first visit to the United ...
(Date:10/31/2014)... MA (PRWEB) October 31, 2014 Following ... hosting a free learning webinar to introduce its new ... standards directors and biostatisticians. , Launched in September, Formedix ... company's suite of clinical trial automation tools. For the ... a web browser. And by introducing Formations – a ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6China to Dominate Caustic Soda Market Through 2018, Says Merchant Research & Consulting in Its New Study 2Charm Sciences Hosts Executives from Latin America for Dairy Safety Executive Seminar 2Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2
... Inc. (Nasdaq: BIOD ) today reported financial results ... Third Quarter Operating Highlights During Biodel,s third ... completed Phase 1 testing of two new ultra-rapid-acting formulations of ... supported investigators at Oregon Health and Sciences University who have ...
... 4, 2011 Vermillion, Inc. (NASDAQ: ... for the second quarter ended June 30, 2011. Key milestones we ... Performance of an estimated 3,920 OVA1® tests during ... 3,200-3,500 tests and representing volume growth of 27% over the ...
... carbon nanofiber-filled coatings devised by researchers from the National ... University outperformed conventional flame retardants used in the polyurethane ... 160 percent and perhaps by as much as 1,130 ... journal Polymer ,* suggest that significant fire-safety advantages ...
Cached Biology Technology:Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 6Vermillion Reports Results for the Second Quarter 2011 2Vermillion Reports Results for the Second Quarter 2011 3Vermillion Reports Results for the Second Quarter 2011 4Vermillion Reports Results for the Second Quarter 2011 5Vermillion Reports Results for the Second Quarter 2011 6Vermillion Reports Results for the Second Quarter 2011 7Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:10/29/2014)... both genetic and environmental, have been blamed for ... Some, such as a family history of schizophrenia, ... Toxoplasma gondii , a parasite transmitted by ... viewed with skepticism. , A new study by ... at the University of Pennsylvania,s School of Veterinary ...
(Date:10/29/2014)... York City on September 19, 2014, leading geneticist and ... of Genome Sciences and Medicine at the University of ... of Tel Aviv University, was awarded the 2014 Lasker-Koshland ... to her honorary degree from TAU, Prof. King was ... Medicine, and for the past 18 years she has ...
(Date:10/29/2014)... potential of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen ... these into a human-readable text developed in manuscript within ... used to study the species distributions of ten Nearctic ... BOLD is originally designed to support the generation and ...
Breaking Biology News(10 mins):Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
... High levels of the stress hormone cortisol may contribute to ... fund managers during financial crises, according to a new study. ... the financial world exhibit risk averse behaviour during periods of ... needs them to take risks and that this change ...
... of new microbes While many endemic infectious ... continue to emerge to threaten human and animal health. ... humans and their livestock but extend to wildlife ecosystems; ... human interventions. The changes in the scale and ...
... often associated with cancer development. In a new study ... Biology researchers at Karolinska Institutet in Sweden have ... role in the correct segregation of chromosomes. Normally ... to two daughter cells. However, tumour cells frequently have ...
Cached Biology News:Stress hormones in traders may trigger 'risk aversion' and contribute to market crises 2Stress hormones in traders may trigger 'risk aversion' and contribute to market crises 3Zoonotic diseases and global viral pandemics 2Zoonotic diseases and global viral pandemics 3
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
...
Biology Products: